Gastroenterology Hadjiliadis D, Khoruts A et. al.
Dec 31st, 2017 - Improved therapy has substantially increased survival of persons with cystic fibrosis (CF). But the risk of colorectal cancer (CRC) in adults with CF is 5-10 times greater compared to the general population, and 25-30 times greater in CF patients after an organ transplantation. To address this risk, the CF Foundation convened a multi-stakeholder task force to develop CRC screening recommendatio...
JAMA Oncology; Kichenadasse, et al
Dec 25th, 2019 - Is high body mass index associated with survival outcomes with atezolizumab therapy, an immune checkpoint inhibitor, in patients with non–small cell lung cancer?
International Journal of Cancer; Carolyn E. Eberle et al
Dec 4th, 2019 - Many hair products contain endocrine‐disrupting compounds and carcinogens potentially relevant to breast cancer. Products used predominately by black women may contain more hormonally‐active compounds. In a national prospective cohort study, we examined the association between hair dye and chemical relaxer/straightener use and breast cancer risk by ethnicity.
Obstetrics & Gynecology; ACOG
Nov 30th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheritance. The most common hereditary cancer syndromes related to women’s cancer include hereditary breast and ovarian cancer syndrome, Lynch syndrome, Li...
Annals of Internal Medicine; Holger J. Schünemann, et al
Nov 30th, 2019 - This synopsis of the European Breast Guidelines provides recommendations regarding organized screening programs for women aged 40 to 75 years who are at average risk. The recommendations address digital mammography screening and the addition of hand-held ultrasonography, automated breast ultrasonography, or magnetic resonance imaging compared with mammography alone. The recommendations also dis...
Nov 30th, 2019 - A rare form of skin cancer may sometimes start with cancer-causing mutations in hair follicle stem cells. A better understanding of how melanoma arises may lead to ways to detect and treat the disease earlier.
JNCCN Ettinger DS, et al
Nov 30th, 2019 - The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as “preferred interventions,” whereas others are categori...
JNCCN Gilligan T, et al
Nov 30th, 2019 - Testicular cancer is relatively uncommon and accounts for <1% of all male tumors. However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past several decades. Several risk factors for testicular cancer have been identified, including personal or family history of testicular cancer and cryptorchidism. Test...
NEJM Bakker MF, et al
Nov 27th, 2019 - Extremely dense breast tissue is a risk factor for breast cancer and limits the detection of cancer with mammography. Data are needed on the use of supplemental magnetic resonance imaging (MRI) to improve early detection and reduce interval breast cancers in such patients.
JAMA Oncology; Mayadev JS, et al
Nov 26th, 2019 - Is immunotherapy after chemoradiotherapy in node-positive cervical cancer tolerable?
Nov 26th, 2019 - Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer
J National Cancer Institute; Deshmukh AA, et al
Nov 18th, 2019 - Squamous cell carcinoma of the anus (SCCA) incidence is rising in the United States (US). Study of incidence trends by stage at diagnosis, age-specific and birth cohort patterns, and trends in mortality could provide evidence for a true increase and etiological clues for this rise.
Cancer Therapy Advisor; Thomas M. Habermann
Nov 13th, 2019 - Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma that is potentially curable. DLBCL is the most common non-Hodgkin lymphoma (NHL) representing about 30% of all cases of NHL in the United States of America (USA) and Europe. There are over 76 different types of lymphoma. It is essential to establish the correct histological diagnosis prior to treatment.
JNCCN Motzer RJ, et al.
Nov 13th, 2019 - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non–clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-lin...
Annals of Oncology; Tilly H et al
Nov 13th, 2019 - Diffuse large B-cell lymphoma is relatively common and represents 30%–58% of non-Hodgkin’s lymphomas. The updated ESMO Clinical Practice Guidelines provide information on the current management of diffuse large B-cell lymphoma including recommendations for screening and diagnosis, staging and risk assessment and stage-matched therapeutic strategies including specific recommendations for young a...
JAMA Oncology; Mukama T, et al
Nov 13th, 2019 - At what age should women with differing family histories of breast cancer start screening?
ASCO Post; Stenger M
Nov 11th, 2019 - In a trial reported in The Lancet, Sessler et al found no difference in breast cancer recurrence after surgery with regional anesthesia-analgesia using paravertebral block and propofol vs general anesthesia with the volatile anesthetic sevoflurane and opioid analgesia. They also found no difference in persistent incisional pain between approaches.
Nov 11th, 2019 - Results from a preliminary research study showed the majority of patients aged 85 years and older were still alive in the short-term after undergoing segmental colectomy for stage II and III colon cancer. Kaur et al presented these findings at the American College of Surgeons Clinical Congress 2019.
Nov 10th, 2019 - This week, we’ll review an interim analysis of the CASPIAN trial, which evaluated the addition of durvalumab to etoposide plus platinum chemotherapy for extensive-stage small cell lung cancer. Then, we’ll talk about two recently issued guidelines on screening for colorectal cancer. Lastly, we’ll summarize some recent FDA approvals and announcements.
Lymphoma Research Foundation;
Nov 6th, 2019 - Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States and worldwide, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year.